Abstract 567P
Background
Leptomeningeal metastasis (LM) is one of the most severe complications of non-small cell lung cancer (NSCLC) and is always accompanied by poor prognosis. The optimal treatment for EGFR–mutated NSCLC patients with LM after EGFR-TKI therapy failure remains unclear. Furmonertinib is a novel third-generation EGFR-TKI. A phase I-II dose-expansion study (NCT03127449) suggested that furmonertinib had a favorable antitumor activity with a wide therapeutic range and minimal toxicity. This retrospective study aimed to evaluate the efficacy and safety of furmonertinib 160mg in combination with bevacizumab and intrathecal chemotherapy in EGFR-mutated NSCLC patients with LM after initial TKI failure in the real world.
Methods
We retrospectively studied 19 NSCLC pts with LM treated with furmonertinib in combination with bevacizumab and intrathecal chemotherapy between February 2021 and April 2023 at Nanjing Chest Hospital. All of them received third-generation EGFR TKIs-based therapies previously. Objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), and toxicity were assessed.
Results
The median age was 57 years (range: 31-77), 6 (31.6%) were males and 13 (68.4%) were females. 4 (21.1%) had EOCG 2, 7 (36.8%) had ECOG 3, and 8 (42.1%) had ECOG 4. 16 patients (84.2%) had partial remission (PR) of LM lesions, 3 patients (15.8%) had stable disease (SD). The intracranial ORR (iORR) was 84.2% and intracranial DCR (iDCR) was 100%. 5 patients achieved PR and 14 patients had SD in the whole lesion, ORR was 26.3% and DCR was 100%. Median PFS was 11.9 months (95% CI 2.8–21.0). The overall survival data were not mature (the overall maturity was 26%). Treatment-related adverse events of ≥ grade 3 occurred in only 1 (5.3%) of 19 patients. Safety profile consistent with previous studies of furmonertinib.
Conclusions
Rechallenges of furmonertinib in combination with bevacizumab and intrathecal chemotherapy has shown significant efficacy and tolerable safety profile in EGFR–mutated NSCLC patients with LM after third-generation EGFR-TKIs treatment failure. The further exploration is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract